source
- Sofinnova Partners raises €725 million for second crossover fund targeting late-stage European biotech firmsSofinnova Partners announced the closing of its second crossover fund with €725 million ($815 million) in commitments. The fund is designed to fill the financing gap for late-stage European biopha…
- Emerging biotech hubs like India could help lower global drug costs by scaling developmentThe article notes that every new therapy raises two core questions: can it be created and can society afford it. Historically biotech has focused on the first question. The author argues that as s…